Skip to search formSkip to main contentSkip to account menu

BRAF NP_004324.2:p.V600E

Known as: NP_004324.2:p.Val600Glu, BRAF V600E, BRAF p.V600E 
A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by glutamic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BRAFV600E-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response
PurposeSeveral studies have shown that different tumour types sharing a driver gene mutation do not respond uniformly to the same… 
2017
2017
Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
2016
2016
The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing
Introduction The BRAF V600E mutation is the most common genetic event in papillary thyroid carcinoma (PTC). The BRAF V600E… 
2016
2016
An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).
107Background: BRAF V600E mutations occur in 1% to 2% of lung adenocarcinomas and act as an oncogenic driver. The BRAF inhibitor… 
2015
2015
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
Genomic profiles of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are still insufficiently understood, and the genetic… 
2015
2015
Expression of haem oxygenase‐1 correlates with tumour aggressiveness and BRAFV600E expression in thyroid cancer
Haem oxygenase‐1 (HO‐1) is an inducible enzyme that participates in haem degradation. Recent studies have indicated that HO‐1… 
2015
2015
Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.
OBJECTIVES Detection of BRAF V600E mutations in hairy cell leukemia (HCL) has important diagnostic utility. In this study, we… 
2014
2014
PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation
Rodić and colleagues analyzed archival melanocytic lesions and cultured melanomas and found no correlation between melanocyte PD… 
2013
2013
BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy
Aim of this work is to provide a detailed comparison of clinical‐pathologic features between well‐differentiated and poorly… 
2011
2011
Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts).
8502 Background: Vemurafenib (PLX4032), an oral, selective inhibitor of oncogenic V600E mutant BRAF, was evaluated for safety and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)